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Glucocorticoid activates glomerular antioxidant enzymes and
protects glomeruli from oxidant injuries
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Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Glucocorticoid activates glomerular antioxidant enzymes and protects
glomeruli from oxidant injuries. We examined the effect of glucocorti-
coid on intrinsic glomerular antioxidant enzyme (AOE) activities.
Munich-Wistar rats were treated with daily i.p. injection of vehicle or
methylprednisolone EMP, 15 mg/kg body wt, (MPI5)] either for three
days or nine days. Glomeruli isolated from rats given MPI5 had
significantly higher activities of total (T-) and manganese (Mn-) super-
oxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase
than vehicle-treated rats (P < 0.05). MPI5-treated rats were subjected
to intrarenal arterial infusion of hydrogen peroxide (35 mol over I hr).
Values for urinary protein excretion rate (UprV) after hydrogen perox-
ide infusion were markedly lower in rats pretreated with MPI5 for both
three days and nine days than in untreated rats (109 18 and 55 24
vs. 416 73g/min, respectively, both P <0.005). To test whether the
same therapeutic intervention attenuates reactive oxygen species
(ROS)-mediated glomerular injury in another model, rats given a single
i.v. dose of puromycin aminonucleoside (PAN) (50 mg/kg body wt)
were treated with daily i.p. injection of vehicle or MPI5. Two days after
PAN administration, when compared to vehicle-treated controls, PAN
rats given MP15 had significantly higher activities of Mn-SOD, GSH-Px
and catalase. After eight days of PAN injection, T- and Mn-SOD
activities were, likewise, significantly higher in MPI5- than vehicle-
treated PAN rats. PAN rats given MP15 also had substantially less
proteinuria, compared to PAN rats given vehicle alone, UprV averaging
32.3 9.4versus 159.0 13.8 mg/24 hr (P < 0.05). Elevated glomerular
matondialdehyde (MDA) level characteristic of PAN rats was absent in
rats treated with MPIS. Moreover, epithelial foot process fusion and
cell vacuolization seen in vehicle-treated PAN rats were markedly
attenuated in MPI5-treated PAN rats. These data indicate that the
mechanism for therapeutic effect of glucocorticoids on ROS-mediated
renal injuries includes an enhancement of endogenous glomerular AOE
activities, which attenuates lipid peroxidation of glomerular tissue,
Several previous studies indicate the pathophysiological im-
portance of the metabolites of partially reduced oxygen mole-
cules, or reactive oxygen species (ROS) in various animal
models of primary glomerulopathy. In these studies, ROS have
been demonstrated to be capable of degrading glomerular
basement membrane [1], and inducing glomerular injury char-
acterized by impaired glomerular filtration and sieving function
[2—4]. Of note, in order to degrade toxic ROS, cells are
equipped with various antioxidant systems including antioxi-
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dant enzymes (AOEs) [5, 6]. Therefore, it is reasonable to
speculate that development of tissue injury depends upon the
balance between generation of ROS and tissue antioxidant
defense mechanism [6, 7]. Indeed, it has been shown that
experimental manipulation of tissue antioxidant systems
achieved by selenium intake restriction, supplementation of
AOEs or non-enzymatic antioxidants, resulted in changes in the
susceptibility of tissues or cells to injury caused by ROS [3,
7—12]. In addition, our recent study has demonstrated that
glomerular-intrinsic AOE activities can be modulated by the
insult of ischemialreperfusion, and that the resultant enhanced
AOE activities provide kidneys with an effective defense mea-
sure against ROS-mediated acute renal failure [13].
Treatment with glucocorticoid is one of several experimental
maneuvers which have been demonstrated to alter tissue/cell
levels of AOEs [14—18]. Frank, Lewis and Sosenco [16] have
shown that treatment of pregnant rats in late gestation with
glucocorticoid raises AOE activities in fetal lungs and protects
them against oxygen toxicity. In addition, in vitro studies by
Randhawa et al [17, 18] have suggested that glucocorticoids can
act directly on fetal lung explants or fibroblasts in culture to
increase AOE activities.
Glucocorticoids are widely used to treat various forms of
glomerulonephropathy in humans. Moreover, previous animal
studies demonstrated that glucocorticoid administration re-
sulted in functional and morphological preservation in several
experimental renal diseases, such as, murine lupus nephritis
[19—21], anti-GBM antibody disease [22], passive Heymann
nephritis [231, and puromycin aminonucleoside (PAN) nephro-
sis [24, 25]. In some of these disorders, it has been speculated
that glucocorticoids exert therapeutic effects mainly through
their immunosuppressive and anti-inflammatory effect, such as
inhibition of antibody production or suppression of infiltrating
leukocyte accumulation and secretion of cytokines [22, 26, 27].
However, in PAN nephrosis, characteristics of which closely
resemble those of human minimal change disease (MCD), and
lacking clear evidence for immunological or inflammatory
events, the mechanism for the therapeutic effects of glucocor-
ticoids has not been elucidated. Of note, several recent studies
provided evidence that the glomerular injury induced by PAN is
mediated by ROS [28—30]. Given these observations above, we
were intrigued by the possibility that glucocorticoids may affect
the severity of ROS-mediated glomerular injury by raising the
local glomerular level of AOE activities.
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In the present study, therefore, we examined the potential
beneficial effect of glucocorticoid in two forms of ROS-medi-
ated injury: a model of intrarenal infusion of hydrogen peroxide
and PAN nephrosis. Although hydrogen peroxide itself is not an
oxygen free radical, it reacts with superoxide anion in the
presence of iron to generate the hydroxyl radical, one of the
potent ROS with marked tissue toxicity. The hydrogen perox-
ide infusion model has recently been developed by us and been
demonstrated to have transient massive proteinuria with im-
pairment of glomerular molecular size selectivity [4]. We aimed
at addressing the following previously untested issues: 1)
whether the AOE activities within the glomerulus can be
augmented by treatment with glucocorticoid and, if so, 2)
whether the enhanced levels of the AOE activities play a key
role in attenuating glomerular injury mediated by ROS.
Methods
Figure 1 illustrates the experimental protocols employed in
the study.
Renal arterial injection of hydrogen peroxide
The first set of protocols examined whether glucocorticoid
modulates AOE activities within normal rat glomeruli and
whether it modifies acute glomerular injury induced by renal
arterial injection of hydrogen peroxide, which has been shown
to induce transient massive proteinuria with impaired molecular
size-selectivity of glomerular capillary wall [4]. Thirty-six adult
male Munich-Wistar rats weighing 190 to 260 g were divided
into four groups. As depicted in Figure 1, rats in Group la (N =
5) and in Group 2a (N = 7) were treated with vehicle for either
three days or nine days, respectively, and rats in Group lb (N
= 5) and in Group 2b (N = 7) were treated with i.p. injection of
methyiprednisolone (MP) in a dose of 15 mg/kg/day (MP15) for
either three days or nine days, respectively. Glomerular AOE
activities, namely those of superoxide dismutase [both total (T-)
and manganese (that is, cyanide-insensitive, Mn-) SOD], gluta-
thione peroxidase (GSH-Px) and catalase were determined in
Group I and Group 2 rats either on Day-4 or Day-b, respec-
tively.
Additional five rats in Group lb and seven rats in Group 2b
were subjected to injection of hydrogen peroxide either on
Day-4 or Day- 10, respectively, in a manner previously de-
scribed by us [41. Following baseline clearance measurements
on the left kidney, including determination of protein excretion
rate, 70 m hydrogen peroxide in 50 m phosphate buffer, pH
7.0, was injected over one hour at the rate of 0.5 mllhr, using the
micropipette infusion system previously described [31]. This
system consists of a micropipette with an internal diameter =50
m connected to a microinfusion pump. Immediately after the
completion of infusion, the pertinent clearance measurements
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Fig. 1. Schematic presentation of the experimental protocols for Group I, 2, 3, 4 and 5 studies. Abbreviations are: PAN: puromycin
aminonucleoside; MDA: malondialdehyde; UprV: urinary protein excretion rate; T- and Mn-SOD: total and manganese superoxide dismutase,
respectively; GSH-Px: glutathione peroxidase.
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were repeated. In our pilot studies, vehicle injection alone was
found not to affect any of the parameters measured. Results
were compared with normal rats not given MPI5 or vehicle
(Group 3, N = 14), seven of which underwent the hydrogen
peroxide injection identical to that of experimental groups. The
remaining seven rats in Group 3 were sacrificed for the MDA
assay described below.
PAN nephrosis model
The second set of protocols examined whether the same
steroid treatment as in Group 1 or 2 modulates the severity of
the glomerular injury of experimental nephrosis induced by a
single injection of PAN. In view of the previous observations by
Thakur, Walker and Shah that antioxidants administered exog-
enously at an early stage of PAN nephrosis (when no protein-
uria is present) can attenuate development of proteinuria [301,
we attempted to ascertain if glucocorticoid is capable of raising
endogenous AOE activities in the early stage of PAN nephrosis.
Thus, Group 4a (N 8) and Group 4b (N = 8) rats were
treated with daily i.p. injection of vehicle or MP15, respec-
tively, for three days (Fig. 1). On Day-2 of this treatment, PAN
(Sigma Chemical Co., St. Louis, Missouri, USA) was adminis-
tered in a dose of 50 mg/kg body wt through the right jugular
vein, given as a single injection over five minutes. Glomerular
AOE activities and glomerular malondialdehyde (MDA) levels
[assessed by thiobarbituric acid (TBA) reactivity] were deter-
mined spectrophotometrically.
Group 5 protocols examined whether MP modulates the
severity of injury at a later stage, when functional and morpho-
logical changes characteristic of PAN nephrosis are otherwise
known to have already been established. Thus, rats in Group 5a
(N = 9) and Sb (N = 11) were treated with vehicle and MP15,
respectively, for nine days. On Day-2, PAN was administered
in the same manner as Group 4. On Day-lO, whole kidney
glomerular filtration rate (GFR) and urinary protein excretion
rate (UprV, based on 24-hour urine collection) were assessed,
followed by measurements of glomerular AOE activities and
MDA levels, as well as morphological examination of the
kidney. Some of the rats in Group 5a and Group 5b were housed
in individual metabolic cage throughout the course of the
experiment to measure daily urinary protein excretion. Further-
more, in order to examine if different doses of MP also
modulate the severity of PAN-induced glomerular injury, rats in
Group 5c (N = 7) and in Group Sd (N = 7) were treated with MP
either in a lower dose (3 mg/kg/day, MP3) or a higher dose (60
mg/kg/day, MP6O), respectively, and subjected to measure-
ments of the various parameters specified above.
Measurement of glomerular AOE activities and MDA levels
Measurement of the activities of glomerular SOD, GSH-Px
and catalase, and MDA levels were performed as follows:
Kidneys were harvested following perfusion with iced 0,9%
NaCI solution. Glomeruli were isolated at 4°C as described [32].
Briefly, minced renal cortex was passed through three consec-
utive sieves, then glomeruli were collected. Glomerular suspen-
sion was washed with 0.9% NaCI solution and centrifuged three
minutes x 2000 rpm twice. The purity of glomerular preparation
was more than 95% by light microscopic examination and was
not different among study groups. Glomeruli were then soni-
cated and stored at —70°C until assay of each enzyme activity.
Measurement of glomerular MDA was performed on the same
day as isolation of glomeruli using freshly sonicated glomerular
suspension.
SOD activities were assayed based on the cytochrome c
autoxidation method developed by McCord and Fridovich [33,
34]. In a 1.6 ml cuvette (with a 10 mm light path), 1.0 ml of
air-saturated 50 m potassium phosphate buffer, 0.1 m
EDTA, pH 7.8 was equilibrated at 25°C with the sample (20 l).
The reaction mixture containing 10 /SM ferricytochrome c
(Sigma Chemical Co., St. Louis, Missouri, USA), 50 M
xanthine (Sigma) and 6 sM xanthine oxidase (Sigma), and either
10 M or I m potassium cyanide was measured for the
reduction of cytochrome c at 550 nm using a Hitachi U-600
spectrophotometer (Tokyo, Japan). Low concentration of po-
tassium cyanide (10 M) was added to avoid possible interfer-
ence by cytochrome oxidase [34]. This concentration has been
shown not to inhibit CuZn- or Mn-SOD activity considerably,
therefore, the activity obtained was considered as total SOD
activity. Mn- (or cyanide insensitive) SOD activity was mea-
sured with 1 m potassium cyanide present [34]. The amount of
SOD required to inhibit the rate of reduction of cytochrome c
by 50% was defined as 1 unit of activity.
GSH-Px activity was measured by the method of Beutler et
al, which uses an oxidation reaction of reduced glutathione by
glutathione peroxidase coupled to the disappearance of
NADPH by glutathione reductase using tert-butyl hydroperox-
ide as the substrate [35]. The assay mixture contains 730 d of
0.1 M Tris-HCI, 0.5 mivi EDTA buffer, pH 7.6, 100 1.d sonicated
sample suspension, 20 d of 2 mM glutathione, 50 il of 0.2mM
NADPH (Sigma) and I U of yeast glutathione reductase (Sig-
ma). After preincubation of the mixture for 15 minutes at room
temperature, the reaction was started by adding 0.35 mri
tert-butyl hydroperoxide (Sigma) and was followed at 340 nm
for five minutes. The activity was calculated using extinction
coefficient of NADPH at 340 nm, 6.22 mrr' cm'.
Catalase activity was measured using the method of Aebi
[36]. In a 1.6 ml quartz cuvette, 25 d of sample was added to
725 d of a mixture containing 7.7 m'vi H202 in 10 m phosphate
buffer, pH 7.0. Change in absorbance at 240 nm was measured.
The rate constant of a first order reaction (k) was used as a unit
by the equation:
k = (1/zt) x In(A1/A2)
where zt is the measured interval (sec); A1 and A2 are the
absorbances at initial and final measurement points, respec-
tively.
Glomerular MDA levels were determined based on the
method described by Uchiyama and Mihara [37]. A standard of
MDA was prepared by the hydrolysis of l,1,3,3-tetraethoxypro-
pane (Aldrich Chemical Co., Milwaukee, Wisconsin, USA).
One hundred and twenty-five microliters of blank/standard/
sample was mixed in 12 x 75 mm brown glass tube with 750 d
1% phosphoric acid, 250 sl 0.67% TBA aqueous solution.
Following 45 minutes in a warmed water bath (95°C), the
reactant was eluted by n-butanol and the difference of absorb-
ance between 535 and 520 nm was used as TBA concentration.
Values for all enzyme activities and MDA levels were cor-
rected by tissue protein content, measured by the method of
Lowry et al [38].
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Measurement of renal function
In this experiment, rats were anesthetized with an i.p.
injection of mactin (Byk, Constanze, Germany; 100 mg/kg body
wt) and underwent preparatory surgery for whole kidney clear-
ance measurements as previously described [3, 391. Thus, after
tracheotomy, an indwelling polyethylene catheter (PE-50, Clay-
Adams, Parsippany, New Jersey, USA) was placed into the
jugular vein for infusion of plasma, inulin and p-aminohippurate
(PAH). The left femoral artery was catheterized to monitor
mean systemic arterial pressure (MAP), using an electronic
transducer (model P23 ID, Gould, Cleveland, Ohio, USA)
which was connected to a recorder (model 2200S, Gould). The
left ureter was cannulated with PE-lO for the subsequent
collection of urine. Fluid loss due to surgical preparation was
replaced with rat plasma, infused in a volume equal to 1% of
body weight over 30 minutes, followed by a continuous infusion
at the rate of 1.2 mI/hr [39]. After priming dose (0.4 ml) of 0.9%
NaCl containing 6.7% inulin and 0.7% PAH, continuous infu-
sion of this mixed solution was given throughout each experi-
ment at a rate of 1.2 ml/hr.
Following an equilibration period (30 mm), rats underwent
assessment of glomerular function. Urine was collected for
determination of urine flow rate, inulin and PAH concentra-
tions. Arterial blood was collected into capillary tubes (100 gil)
for determinations of plasma inulin and PAH concentrations at
the mid point of urine collection. Two consecutive collections
with each =°10 mm duration were performed.
Inulin concentrations in plasma and urine were determined
by the macroanthrone method [40]. PAH concentrations in
plasma and urine were assayed by the method of Bratton and
Marshall, modified by Smith et al [41]. GFR and renal plasma
flow rate (RPF) were estimated by inulin and PAH clearance,
respectively. Urine protein concentration was assessed by the
Coomassie brilliant blue method [42], and excretion rate (UprV)
was expressed as milligram per 24 hours and microgram per
minute in PAN- and hydrogen peroxide-injected animals, re-
spectively.
Renal morphological examinations
Electron microscopic examinations were performed on
Day-lO in PAN nephrosis model. For electron microscopy,
immediately after kidneys were removed, small tissue blocks
were cut from the cortex and fixed by immersion in 2%
glutaraldehyde in 0.1 M phosphate buffer for two to four days at
4°C. After fixation, tissue blocks were rinsed in 0.1 M phosphate
buffer solution, then post-fixed with osmium tetroxide for one
hour, dehydrated in cold ethanol series, and embedded in Epon.
Thin sections (60 to 80 nm) were stained with 4% aqueous
uranyl acetate and lead citrate and examined with Zeiss elec-
tron microscope. Glomeruli from rats in Group 5a (PAN +
vehicle, N = 3), 5b (PAN + MPI5, N = 3), Sc (PAN + MP3, N
= 3) and 5d (PAN + MP6O, N = 3) were examined in a blinded
fashion. Epithelial cell injury was semiquantitatively assessed
by scoring from 0 to 4+ the severity of vacuolization, microvil-
bus transformation, and the extent of foot process fusion, with
4+ representing nearly 100% capillary loop involvement. Since
no discernible ultrastructural abnormalities were found in gb-
meruli following hydrogen peroxide administration in our ear-
her studies [4], no morphologic assessment was made in the
Group I and 2 rats subjected to hydrogen peroxide injection.
Statistics
All values are expressed as mean 1 SE. For comparisons
among groups, one-way analysis of variance (ANOVA) fol-
lowed by t-test with modification by Bonferroni's method was
performed. P value less than 0.05 was considered as being
statistically significant.
Results
Effect of glucocorticoid on glomerular AOE activities in
normal rats
Values for glomerular T-SOD, Mn-SOD, GSH-Px and cata-
lase activities measured on Day-4 and Day-b are summarized
in Figure 2.
On Day-4, when compared to Group Ia (vehicle-treated
normal rats), Group lb (MP15-treated normal rats) had signifi-
cantly higher values for the activities of T-SOD (on average,
29.0 0.9 vs. 22.0 3.3 U/mg protein, P <0.05), Mn-SOD (on
average, 12.8 0.4 vs. 8.7 0.5 U/mg protein, P < 0.05), and
catalase (1.30 0.13 vs. 0.94 0.08 klmg protein, P <0.05).
Values for GSH-Px activity in Group lb were, however, not
significantly different from those in Group la (on average 87
9 vs. 97 13 U/mg protein) on Day-4.
On Day-lO, values for T-SOD, Mn-SOD and GSH-Px activ-
ities were significantly higher in Group 2b (normal + MPI5)
than Group 2a (normal + vehicle) (30.4 2.1 vs. 24.0 1.0
U/mg protein, P < 0.05, 12.3 0.9 vs. 9.0 0.1 U/mg protein,
P <0.05, and 156 13 vs. 106 18 U/mg protein, P < 0.05,
respectively). Likewise, when compared to Group 2a, Group 2b
tended to have heightened level of catalase activity (1.08 0.14
vs. 0.88 0.11 k/mg protein) on Day-lO, although the difference
did not reach statistical significance. Thus, MP15 led to en-
hanced gbomerular T-SOD, Mn-SOD, GSH-Px and catalase
activities in these normal healthy rats.
Effect of glucocorticoid on hydrogen peroxide-induced
proteinuria
Results for UprV before and after hydrogen peroxide injec-
tion in Group lb (normal rats treated with MPI5 for 3 days, N
5) and Group 2b (normal rats treated with MPI5 for 9 days,
N = 7) were compared with those obtained from Group 3
(untreated normal rats, N 7) and are summarized in Figure 3.
Values for UprV before hydrogen peroxide injection in Group
lb (on average, 3.0 0.7 ig/min) and those in Group 2b (4.3
1.2 g/min) were comparable to those in Group 3 (4.8 0.8
g/min). In contrast, values after hydrogen peroxide injection
in Group lb (on average, 108.5 17.8 .tgImin) and those in
Group 2b (55.0 24.1 g/min) were significantly lower than
those in Group 3 (415.9 73.4 g/min, both P < 0.005). Thus,
MPI5-treated normal rats, which had elevated AOE activities,
showed remarkably efficient resistance against proteinuric ef-
fect of hydrogen peroxide.
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Fig. 2. Glomerulartotal (T-, top left) and
manganese (Mn-, top right) superoxide dismutase
(SOD), glutathione peroxidase (GSH-Px, bottom
left) and catalase (bottom right) activities in Group
Ia and lb (normal rats given vehicle and
_] * methylprednisolone 15 mg/kg/day for 3 days,
U—I respectively) and 2a and 2b (normal rats given
vehicle and methylprednisolone 15 mg/kg/day for 9
days, respectively). The numbers in circles denote
the number of animals. T-SOD, Mn-SOD and
catalase activities were significantly increased in
Group lb vs. Group Ia, and T.SOD, Mn-SOD and
GSH-Px activities were significantly increased in
Group 2b vs. Group 2a. Values are expressed as
mean SE. * P < 0.05.
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Fig. 3. Baseline urinary protein excretion rate (before) and after left
renal arterial hydrogen peroxide (35 mivi over I hr) infusion in Group lb
[normal rats treated with methylprednisolone 15 mg/kg/day (Lx) for 3
days, N = 5), Group 2b [normal rats treated with MP15 (O)for 9 days,
N = 7] and Group 3 [untreated normal rats (•), N = 7). The marked
proteinuria seen following hydrogen peroxide infusion was significantly
reduced by treatment with MPI5. Values are expressed as mean SE.
* P < 0.005.
Effect of glucocorticoid on glomerular AOE activities in PAN
nephrosis
Values for glomerular T-SOD, Mn-SOD, GSH-Px and cata-
lase activities in PAN-treated rats (PAN rats) are summarized
in Figure 4 A and B.
On Day-4, when compared to Group 4a (vehicle-treated PAN
rats), Group 4b (MPIS-treated PAN rats) had significantly
higher values for the activities of Mn-SOD (on average, 11.1
0.9 vs. 8.2 0.8 U/mg protein, P < 0.05), GSH-Px (159 25 vs.
87 11 U/mg protein, P <0.05) and catalase (1.47 0.09 vs.
1.19 0.10 k/mg protein, P < 0.05). Values for T-SOD
activities in Group 4b were, however, not statistically signifi-
cantly different from those in Group 4a (on average 36.5 3.7
vs. 33.0 5.3 U/mg protein) on Day-4.
On Day-b, values for T- and Mn-SOD activities were signif-
icantly higher in Group Sb (PAN + MPIS) than Group 5a (PAN
+ vehicle) (53.0 3.2 vs. 33.2 4.5 U/mg protein, P < 0.05 and
14.5 1.2 vs. 9.8 0.6 U/mg protein, P < 0.05, respectively).
Likewise, when compared to Group Sa, Group 5b tended to
have heightened levels of GSH-Px and catalase activities (142
8 vs. 120 23 U/mg protein and 1.00 0.09 vs. 0.57 0.08
k/mg protein) on Day-b, although the difference in both en-
zyme activities did not reach statistical significance. Of interest,
in Group Sc (MP3-treated PAN rats) and Sd (MP6O-treated PAN
rats), values for the activities of T-SOD (averaged 22.5 2.0
and 27.5 3.4 U/mg protein, respectively), Mn-SOD (7.0 0.9
and 9.0 0.8 U/mg protein, respectively), GSH-Px (68 8 and
91 17 U/mg protein, respectively) and catalase (0.70 0.16
and 0.68 0.20 k/mg protein, respectively) remained at levels
lower than or similar to those of Group 5a described above.
Values for T- and Mn-SOD activities were significantly lower in
both Group 5c and Sd than those measured in Group Sb. Thus,
neither MP3 nor MP6O led to enhancement of glomerular AOE
activities.
To ascertain whether MP directly affects our AOE activity
assays, we measured glomerular AOE activities in samples with
or without iO to l0— M MP. The differences in values within
these pairs of samples were less than 2.0% (N 5), 1.7% (N =
3) and 1.6% (N = 5) for the assays of T-SOD, GSH-Px and
catalase, respectively. Therefore, MP did not directly affect
these AOE assays to any appreciable degree.
Overall, daily 15 mg/kg body wt of MP administration, but
not lower or higher dose, raised glomerular AOE activities,
particularly that of Mn-SOD in PAN rats measured three days
and nine days after the administration.
Effect of glucocorticoid on glomerular function and MDA
levels in PAN nephrosis
Values for the 24-hour urinary protein excretion of six rats in
Group Sb (PAN + MP1S) were compared with those obtained
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Fig. 4. Activities of glomerular total (T-, top) and manganese (Mn-, bottom) superoxide dismutase (SOD) in Groups 4 and 5 (A), and glutathione
peroxidase (GSH-Px, top) and catalase (bottom) in Groups 4 and5 (B). As illustrated, both T- and Mn-SOD activities were increased in puromycin
aminonucleoside (PAN)-treated rats by treatment with methylprednisolone 15 mg/kg/day (MP15), but not by treatment with either vehicle or
methylprednisolone 3 mg/kg/day (MP3) or 60 mg/kg/day (MP6O). The numbers in circles denote the number of animals. Values are expressed as
mean SE. * P < 0.05.
from five rats in Group 5a (PAN + vehicle) and are illustrated
in Figure 5. In Group 5a, marked increase in proteinuria was
first apparent on Day-7 (5 days after PAN administration) and
the proteinuria increased thereafter reaching 164.6 20.3
mg/day by Day-b. In contrast, Group 5b rats had markedly
attenuated proteinuria throughout the course of the disease with
maximum urinary protein excretion on Day-lO (37.0 10.4
mg/day).
Table 1 summarizes values for gbomerular functional param-
eters measured on Day-10 in Groups 5a, Sb, Sc, Sd and 2a.
Group 5a (PAN + vehicle, N = 9) had significantly lower levels
of GFR (on average, 0.42 0.04 mI/mm) and higher UprV (159.4
13.8 mg/24 hr), compared to those of Group 2a (normal +
vehicle, N 7) (0.82 0.05 mI/mm and 3.2 0.5 mg/24 hr,
respectively), patterns characteristic of the PAN nephrosis
model. In contrast, Group Sb (PAN + MPIS, N = 11), which
had significantly higher glomerular AOE activities than Group
5a, showed significantly and markedly less proteinuria than
Group Sa, the UprV values averaging 32.3 9.4 mg/24 hr,
although values for GFR were comparable between the two
groups. Group Sc (PAN + MP3, N = 7) and Group Sd (PAN +
MP6O, N = 7), neither of which had elevated gbomerular AOE
activities, had significantly higher levels of proteinuria than
Group Sb, UprV values averaging 146.5 16.2 and 146.9 39.7
mg/24 hr, respectively, which were values indistinguishable
from that in PAN rats not given MP (Group 5a). Values for
hematocrit in Group Sb (54.9 0.7 vol %) were not different
from those in Group 5a (53.4 0.7 vol %) or Group Sc (54.S
0.8 vol %), or Group Sd (S3.4 0.7 vol %), orGroup 2a (53.2
0.5 vol %).
Values for glomerular MDA levels on Day-4 and Day- 10 are
presented in Figure 6. On Day-4, both Group 4a and Group 4b
had significantly elevated levels of gbomerular MDA, when
compared to Group 3 (untreated normal rats; on average, 1.08
0.18 and 1.40 0.24 vs. 0.40 0.08 nmol/mg protein, both P
<0.05). Values for MDA on Day-b in Group Sa (on average,
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Time, days
Fig. 5. Time course of proteinuria in Group 5a •, puromycin amino-
nucleoside (PAN)-treated rats given vehicle] and Group Sb [0, PAN
rats given methy!prednisolone 15 mg/kg/day (MPI5)]. The marked
proteinuria seen after Day-7 in Group 5a was largely abolished by
treatment with MPI5. Values are from S rats in Group 5a and 6 rats in
Group Sb as indicated in parentheses and are expressed as mean SE.
* P < 0.01.
0.82 0.10 nmol/mg protein) were still significantly higher than
those of normal control animals (Group 3). In contrast, Group
5b had MDA values (on average, 0.31 0.09 nmol/mg protein)
significantly lower than those of Group 5a and comparable to
those of normal animals (Group 3). Groups Sc and 5d, both of
which had neither elevated glomerular AOE activities nor
resistance against proteinuric effect of PAN, showed MDA
levels on Day-tO (on average, 0.70 0.06 and 0.84 0.22
nmol/mg protein, respectively) markedly elevated over those of
Group Sb and normal rats, but comparable to those of Group 5a
PAN rats not given MP.
To ascertain whether the presence of MP affects our MDA
assay per Se, we added MP (10—v to j—3 M) to each of the MDA
standards (0, 1, 2 and 4 nmol/ml). The slopes of the regression
lines calculated for MDA concentration (x-axis) per absorbance
(y-axis) were statistically not different between the MDA stan-
dards with (y = 0.012 x + 0.009) versus without MP ( y 0.012
x + 0.01). Therefore, MP did not directly affect the MDA assay.
The degree of epithelial cell injury in PAN-treated rats was
semiquantitatively assessed by electron microscopy, and the
results are summarized in Table 2. Glomeruli from Group 5a
(PAN + vehicle, N = 3) and Group Sc (PAN + MP3, N = 3)
showed equally severe microvillous transformation and vacu-
olization and extensive foot process fusion. In contrast, glomer-
uli from Group Sb (PAN + MP1S, N = 3) had only mild
microvillous transformation without foot process fusion or
vacuolization. Group Sd (PAN + MP6O, N = 3) had morpho-
logical changes intermediate of those in Group Sa and Group Sb.
These morphological changes are illustrated in Figures 7A
and 7B from glomeruli of Group 5a (A) and Group Sb (B) on
Day-b. While epithelial cell lesions, such as effacement of foot
processes, microvillous transformation and cell vacuolization,
were prominent in Group Sa (PAN + vehicle), they were
markedly attenuated in Group Sb (PAN + MPI5).
Discussion
In the present study, the treatment with MPI5 for both three
days and nine days led to elevation of glomerular AOE activi-
ties in normal rats. Based on previous observations by others
GFR
mI/mm
UprV
mg/24 hr
Hematocrit
vol %
Group 5a 0.42a 1590b,c 534
(PAN + vehicle)
Group 5b O.4I 32.3 54.9
(PAN + MPIS)
Group Sc 0.43a 1465b,c
(PAN + MP3) 16.2
Group Sd 0.39a 19b.c 53•4
(PAN + MP6O)
Group 2a 0.82 3.2 53.2
(normal + vehicle)
Treatment with methylprednisolone 15 mg/kg/day in puromycin rats
(Group Sb, PAN + MPIS) markedly attenuated proteinuria without
altering GFR or hematocrit appreciably. Values are from 9 rats in
Group Sa, 11 rats in Group Sb, and 7 rats each in Group Sc, 5d and 2a,
and are expressed as mean SE.
a P < 0.005 vs. Group 2a
b P < 0.05 vs. Group 2a
P < 0.05 vs. Group Sb
that fetal rat lung AOE activities markedly increased late in
gestation 143, 44] with high serum concentration of glucocorti-
coids [45], and that treatment of pregnant rats in late gestation
with dexamethasone accelerated maturation of lung AOE sys-
tem [16], glucocorticoids have been speculated to play an
important homeostatic role in regulating AOE production in the
prenatal period [181. Moreover, a recent study by Hayashibe et
al demonstrated that a maturation of AOE system occurred not
only in the fetal lung but also in the kidney and that the
maturational increase in AOEs was even more dramatic in the
kidney than in the lung [46]. Collectively, these observations
point to a potentially important functional role of AOEs within
the kidney with modulation by glucocorticoids. Indeed, the
present study demonstrated that glucocorticoid administration
raises AOE activities measured in isolated glomeruli. Together
with our recent in vitro observation that glucocorticoid raised
Mn-SOD and catalase activities in cultured glomerular endothe-
hal cells [47], it appears that glucocorticoids can enhance
glomerular AOE activities through their direct local actions.
To test the functional importance of the augmented glomer-
ular AOE activities by glucocorticoid, normal rats treated with
MP15 for three days (Group lb) and for nine days (Group 2b)
were subjected to a direct form of ROS insult, that is, intrarenal
arterial infusion of hydrogen peroxide. In these kidneys with
enhanced glomerular AOE activities, our experimental attempt
to selectively elevate local level of ROS [4] resulted in only a
mild proteinuria, contrasting to the massive proteinuria found in
normal rats without glucocorticoid (Group 3) and without
activation of AOE (Fig. 6). In our recent study [4], exogenous
administration of catalase or iron chelator prior to the insult
attenuated hydrogen peroxide-induced proteinuria, suggesting
that proteinuria in this model is mediated by hydrogen perox-
ide-derived metabolites including hydroxyl radical, one of the
potent ROS with marked tissue toxicity. Therefore, it is plau-
sible that the augmented AOE levels with MPIS treatment,
especially of GSH-Px and catalase, had a crucial impact on the
glomerular sieving defect induced by hydrogen peroxide.
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Table 1. Summary of glomerular function and hematocrit in Groups
5a, Sb, 5c, Sd and 2a
(5)
(6)
4 5 6 7 8 9 10
Day-4
Group 3 Norman
Group 4a (PAN + Vehicle)
Group 4b (PAN + MP1 5)
Day-iD
Group 3 (Normal)
Group Sa (PAN + Vehicle)
Group 5b (PAN + MP1EI
Group 5c (PAN + MP3)
Group Sd (PAN + MPEUi
111*
111*
111*
I I I
0.5 1.0 1.5
nmolimg protein
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Fig. 6. Glomerular malondialdehyde (MDA)
levels in Groups 3, 4 and 5. The numbers in
circles denote the number of animals. As
shown, puromycin aminonucleoside (PAN)
treatment resulted in increased glomerular
MDA levels. Whereas treatment with
methylprednisolone 15 mg/kg/day (MP15)
reduced MDA by Day-b, neither vehicle nor
methylprednisolone 3 mg/kg/day (MP3) nor 60
mg/kg/day (MP6O) had any effect on MDA.
Values are expressed as mean SE. * J <
0.05.
Table 2. Semiquantitative analysis of electron microsc
Groups 5a, 5b, 5c and Sd
opic findings in
Foot
Microvilbous process
transformation fusion Vacuolization
Group 5a (PAN + vehicle)
#1 3+ 3+ 3+
#2 3+ 4+ 3+
#3 3+ 3+ 4+
Group Sb (PAN + MP15)
#1 1+ 0 0
#2 1+ 0 0
#3 1+ 0 0
Group Sc (PAN + MP3)
#1 3+ 4+ 3+
#2 3+ 3+ 3+
#3 4+ 4+ 4+
Group Sd (PAN + MP6O)
#1 1+ 1+ 1+
#2 2+ 2+ 1+
#3 1+ 1+ 0
The degree of glomerular epithelial cell injury was semiquantitatively
assessed by scoring from 0 to 4+. Treatment of puromycin rats with
methylprednisobone 15 mg/kg/day (Group Sb, PAN + MPI5) markedly
attenuated epithelial cell injury seen in puromycin rats given vehicle
(Group 5a, PAN + vehicle).
In our second study, in order to test whether the same steroid
treatment protocol which increased AOE levels in normal rats
has a beneficial therapeutic effect on glomerular injury induced
by PAN, PAN rats were treated with MP15 either for three days
or nine days. PAN administration is known to induce structural,
functional and biochemical changes in rat glomeruli closely
resembling those of human MCD [48, 49]. Thus, in our study, a
single i.v. dose injection of PAN resulted in marked proteinuria
and abnormal ultrastructure of glomerular epithelial cells
(Group 5a) characteristic of human MCD. Of further analogy to
human MCD, daily administration of an intermediate dose of
glucocorticoid was found in our study to remarkably attenuate
the proteinuria throughout the course of the disease and also
attenuate abnormal epithelial cell morphology of PAN-treated
rats (Group 5b) examined on Day-b. Moreover, glucocorticoid
given in either lower or higher doses exerted less beneficial
effect on the damage of glomerular structure or function,
although treatment with higher doses led to mild improvement
in morphological changes.
In our attempt to further clarify the biological mechanism
underlying the therapeutic effect of glucocorticoid, we paid
special attention to the recently formulated notion that ROS
plays a key pathogenic role in the PAN model. In several
studies, exogenous administration of SOD, allopurinol, or cat-
alase has been shown to attenuate PAN-induced proteinuria
[28, 29]. Moreover, Thakur, Walker and Shah demonstrated
that a hydroxyl radical scavenger, dimethylthiourea, and an
iron chelator, deferoxamine, had protective effect on the kidney
from PAN-induced proteinuria even when these drug therapies
were discontinued prior to the otherwise-expected time of the
onset of proteinuria [30]. On the basis of these observations, it
is plausible that the interaction between hypoxanthine (an
intermediate metabolite of PAN) and xanthine oxidase results
in generation of superoxide and hydrogen peroxide, which, in
turn, interact with iron to generate hydroxyl radical. Thus, all
these three forms of ROS can potentially play key roles in the
pathogenic process of PAN nephrosis. Alternatively, Tada et al
[50] observed that the activities of renal mitochondrial en-
zymes, such as NADP-cytochrome c reductase, succinate-
>
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Fig. 7. E!ectronmicrographs taken from glomeruli of Group 5a (A) andGroup Sb (B) on Day-jO. Epithelial cell lesions, such as effacement of foot
processes (arrows), microvillous transformation and cell vacuolization, which were prominent in puromycin aminonucleoside-treated rats given
vehicle (Group 5a), were markedly attenuated by treatment with methylprednisolone 15 mg/kg/day (Group 5b). (Magnification X 37500).
cytochrome c reductase and cytochrome c oxidase, were de-
creased in the rat kidney obtained 84 hours after PAN injection,
and suggested that PAN induces mitochondrial electron-trans-
port dysfunction. Since decrease in rnitochondrial electron-
transport activity is likely to promote incomplete reduction of
oxygen, it is conceivable that ROS are generated in abundance
from mitochondria in PAN-treated kidney and, therefore, an-
tioxidant systems within mitochondria, such as Mn-SOD, play
an important role in scavenging ROS in this model.
In this regard, the present study provided several lines of
evidence, each indicating that the mechanism of the therapeutic
effect of glucocorticoid on minimal change disease (MCD)
might be channeled through its potential to interfere with this
very key pathogenic action of ROS on the glomerulus. Thus, by
measuring the activities of three enzymes crucial for degrada-
tion of ROS in glomeruli isolated from six experimental groups
(Fig. 4 A and B), we found that an intermediate dose glucocor-
ticoid raises AOE activities, particularly that of SOD, within
the glomerulus. The contention that this capability of glucocor-
ticoid to activate AOE had a crucial impact on the glomerular
damage caused by PAN was suggested by several additional
findings. First, PAN rats either given a lower (Group 5c) or
higher dose glucocorticoid (Group Sd) had AOE levels just as
low as PAN rats not treated with glucocorticoid (Group 5a), and
manifested just as severe proteinuna. Second, perhaps more
compellingly, these effects of glucocorticoid on AOE and the
degree of PAN-induced glomerular injury were closely associ-
ated with the level of lipid peroxidation, as estimated by the
level of glomerular MDA content, an indirect parameter for
lipid peroxidation products resulting from ROS-induced tissue
injury. Thus, Group 5b given an intermediate dose glucocorti-
coid, had remarkably elevated AOE levels and showed remark-
able protection from ROS-induced injury, and the degree of
lipid peroxidation was no higher than normal healthy control
animals (Group 3) (Fig. 6). In contrast, in Group Sa PAN rats
not given glucocorticoid, or Group Sc or Sd PAN rats given a
lower or a higher dose of glucocorticoid, respectively, compa-
rably severe impairment of glomerular sieving function and
similarly low levels of AOE activities were accompanied by
evidence for equally advanced lipid peroxidation (Fig. 6).
Furthermore, we found that PAN rats given an intermediate
dose of glucocorticoid (Group Sb) had enhanced AOE levels not
only on Day-b but also on Day-4 (when proteinuria is known
not to occur in this model). Since previous studies indicate that
the kidney is programmed very early after PAN injection to
develop proteinuria [51], and that ROS generation which leads
to subsequent development of proteinuria may occur during the
initial period of PAN-induced injury [30], early enhancement of
AOE activities may play an important role in protecting the
kidney from PAN-induced proteinuria.
Where the mechanism underlying the observed MP-induced
AOE activation is concerned, glucocorticoids have multiple
biological effects on tissue/cell function)2 Thus, enrichment of
'It is unlikely that MP per se interfered with the metabolism of PAN,
or glomerular AOE/MDA assays. Previous studies in humans and
animals demonstrated that the plasma and tissue half-life of MP was 2
to 3 hours and less than 6 hours, respectively, when administered
intravenously [53, 54]. In the present study, since PAN was injected in
the mid point of MP treatment with a 12 hour interval between previous
and following MP treatment, and glomeruli for AOE/MDA assays were
harvested 24 hours after the last injection of MP, the prevailing MP
level was considered to be too low to affect the uptake or the binding of
PAN or AOE/MDA assays. Furthermore, our experiments to ascertain
whether the presence of MP affects AOE/MDA assays revealed that the
direct addition of MP did not affect these assays, as discussed in the
Results section.
2 As the biochemical events underlying the activation of AOE by
glucocorticoid remain uncertain, it also remains unknown why the
lower and higher dose of MP were ineffective. In this regard, our
additional findings that PAN rats treated with 30 mg/kg/day MP (N = 3)
had moderate degree of proteinuria on Day-lO (on average, 71.0 28.3
mg/day), suggest that MP exerts its therapeutic effect on PAN-induced
proteinuria in a range of MP dose, but not at a specific single MP dose.
One possible explanation for the lack of therapeutic effect at 60 mg/kg
MP is that the breakdown of enzyme protein was accelerated at higher
dose of MP, but not at lower dose, as demonstrated in muscle protein
[55—57]. It is also possible that the higher dose leads to the down
regulation of glucocorticoid receptor [58, 59] in glomerular cells.
Indeed, an adverse effect of glucocorticoids has been reported in
humans, in which a high-dose glucocorticoid administration to patients
with a nephrotic syndrome caused an increase in proteinuria [60].
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heparan sulfate proteoglycan core protein content known to
occur in response to glucocorticoid [52] may have contributed
to the protection against oxidant-mediated glomerular injury.
Moreover, our most recent study in vivo [61] demonstrated a
direct relationship between AOE activities and the volume
status of the animals. Although values for arterial hematocrit
were not affected by MP in the current study, a subtle volume
expansion induced by mineralocorticoid effect of MP may have
contributed to the increase in AOE activities. In an in vitro
study, we have also learned recently that glucocorticoid can
raise AOE activities within glomerular endothelial cells in
culture [47]. Thus, there are at least two potential mechanisms
for the action of glucocorticoid to raise AOE activities in vivo,
one directly and the other through volume expansion.
We are far from elucidating the mechanisms responsible for
the increase of AOE activities by glucocorticoid. Although
Randhawa et al speculated that glucocorticoid acts to increase
the copper-zinc SOD (CuZn-SOD) activity in cultured lung
explants by causing a decrease in the degradation of the
enzyme, and not by causing an increase in its synthesis [17],
they did not examine if CuZn-SOD gene expression could be
induced by glucocorticoid. Recent studies demonstrated that
tumor necrosis factor selectively increases Mn-SOD mRNA,
without affecting levels of CuZn-SOD and catalase rnRNA in
bovine and mouse endothelial cells [62, 63]. Further studies are
required to investigate the regulation of glomerular AOEs to
determine the specific mechanism involved in the glucocorti-
coid-induced AOE activation demonstrated in our study.
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